Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes participation from new investor ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Detailed price information for Arch Biopartners Inc (ARCH-X) from The Globe and Mail including charting and trades.

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

Now, Shift, a new social venture founded by Dutch entrepreneur ... Supported by a network of Dutch strategic partners and impact financiers, the first Shift landmark will be in the Netherlands ...

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...

JPMorgan event follows the murder of an industry leader and the nomination of a vaccine sceptic as top official ...